Insilico Medicine Surges 11.6% as Strategic Alliance with Purui Pharma Targets Over $2.5B in Potential Value

Insilico Medicine (03696) and Taiwan-listed Purui Pharma established a strategic alliance today with potential collaboration value exceeding $2.5 billion, driving the stock up 11.6% to HK$51.7 as of 11:33 a.m. The partnership aims to integrate Insilico Medicine's Pharma.AI platform capabilities in target discovery, generative chemistry, and molecular optimization with Purui's expertise in global drug development, manufacturing, and commercialization. The two companies plan to develop a next-generation pharmaceutical innovation model combining AI-powered research systems with automated manufacturing and quality execution processes, pending final agreements between the parties.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments